Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Colorectal Neoplasms

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 83 articles:
HTML format



Single Articles


    November 2022
  1. DOI H, Fujiwara M, Beppu N, Yokoyama H, et al
    Neoadjuvant Modified Short-course Radiotherapy for Stage IV Rectal Cancer.
    Anticancer Res. 2022;42:5587-5595.
    PubMed     Abstract available


  2. YUEH TC, Hung YC, Lee HT, Yang MD, et al
    Role of Matrix Metallopeptidase-2 Genotypes in Taiwanese Patients With Colorectal Cancer.
    Anticancer Res. 2022;42:5335-5342.
    PubMed     Abstract available


  3. YAMAUCHI N, Matsuda T, Sawad R, Hasegawa H, et al
    Clinical Significance of Early Recurrence After Curative Resection of Colorectal Cancer.
    Anticancer Res. 2022;42:5553-5559.
    PubMed     Abstract available


  4. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2022;42:5497-5505.
    PubMed     Abstract available


  5. PARK YL, Cho SB, Park SY, Oh HH, et al
    Engulfment and Cell Motility 1 (ELMO1) Regulates Tumor Cell Behavior and Predicts Prognosis in Colorectal Cancer.
    Anticancer Res. 2022;42:5343-5355.
    PubMed     Abstract available


  6. MEIROVITZ A, Baider L, Peretz T, Stephanos S, et al
    PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics.
    Anticancer Res. 2022;42:5487-5496.
    PubMed     Abstract available


  7. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
    Gustave Roussy Immune Score for Predicting Postoperative Complications and Non-cancer Death in Elderly Patients With Colon Cancer.
    Anticancer Res. 2022;42:5643-5653.
    PubMed     Abstract available


  8. KIM SH, Song SE, Baik H, Hur DY, et al
    15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes.
    Anticancer Res. 2022;42:5385-5396.
    PubMed     Abstract available


    October 2022
  9. KATO S, Miyoshi N, Fujino S, Minami S, et al
    Combined Inflammation and Nutrition Factors Reinforce the Prognostic Prediction for Stage III Colorectal Cancer Patients.
    Anticancer Res. 2022;42:4989-4999.
    PubMed     Abstract available


  10. CHOMICKI S, Chapet S, Drifa M, Ouaissi M, et al
    Outcomes and Side Effects of Preoperative Chemoradiotherapy for Locally Advanced Upper Rectal Cancer.
    Anticancer Res. 2022;42:4833-4840.
    PubMed     Abstract available


  11. OZATO Y, Masuda T, Kobayashi Y, Takao S, et al
    PRKRIP1, A Splicing Complex Factor, Is a Marker of Poor Prognosis in Colorectal Cancer.
    Anticancer Res. 2022;42:4701-4706.
    PubMed     Abstract available


  12. RYU S, Kitagawa T, Goto K, Okamoto A, et al
    Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery.
    Anticancer Res. 2022;42:4849-4856.
    PubMed     Abstract available


  13. ZHU D, Guo P, Jin XY, Zhang R, et al
    Long-chain Non-coding RNA MIR4435-2HG Expression Correlates With Size of Intestinal Polyps in Children and With Metastasis of Colon Cancer.
    Anticancer Res. 2022;42:4707-4714.
    PubMed     Abstract available


  14. CZAPLA J, Drzyzga A, Matuszczak S, Pilny E, et al
    The Complex Composition of Trans-resveratrol, Quercetin, Vitamin E and Selenium Inhibits the Growth of Colorectal Carcinoma.
    Anticancer Res. 2022;42:4763-4772.
    PubMed     Abstract available


  15. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
    Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
    Anticancer Res. 2022;42:4963-4971.
    PubMed     Abstract available


  16. GERGER A, Eisterer W, Fuxius S, Bastian S, et al
    Retrospective Analysis of Treatment Pathways in Patients With BRAF(V600E)-mutant Metastatic Colorectal Carcinoma - MORSE(CRC).
    Anticancer Res. 2022;42:4773-4785.
    PubMed     Abstract available


    September 2022
  17. RUBIO CA, Vieth M, Lang-Schwarz C
    Crypts in Asymmetric Branching in Patients With Ulcerative Colitis in Remission.
    Anticancer Res. 2022;42:4493-4497.
    PubMed     Abstract available


  18. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available


  19. CRISTAUDO AT, Jennings SB, Morris DL
    Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis.
    Anticancer Res. 2022;42:4217-4235.
    PubMed     Abstract available


    August 2022
  20. KAWAMURA H, Honda M, Takano Y, Kinuta S, et al
    Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer.
    Anticancer Res. 2022;42:3921-3928.
    PubMed     Abstract available


  21. KUBOTA Y, Han Q, Hamada K, Aoki Y, et al
    Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Anticancer Res. 2022;42:3857-3861.
    PubMed     Abstract available


  22. YOSHIDA K, Nishi K, Ishikura S, Nakabayashi K, et al
    Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner.
    Anticancer Res. 2022;42:3993-4001.
    PubMed     Abstract available


    July 2022
  23. KATAOKA S, Arita T, Konishi H, Yamamoto Y, et al
    The Role of Inflammation-associated microRNA-4257 as a Promoter of Malignancy in Colorectal Cancer.
    Anticancer Res. 2022;42:3349-3360.
    PubMed     Abstract available


  24. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    Site-specific Performance of ColonView (CV) Fecal Immunochemical Test (FIT) With Differences Between Proximal and Distal Colorectal Adenoma.
    Anticancer Res. 2022;42:3557-3567.
    PubMed     Abstract available


  25. MINAMI S, Miyoshi N, Fujino S, Kato S, et al
    The Geriatric Nutritional Risk Index as a Prognosis Predictor in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3759-3766.
    PubMed     Abstract available


  26. HIRAIDE T, Morita Y, Horikawa M, Sugiyama E, et al
    Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:3313-3324.
    PubMed     Abstract available


    June 2022
  27. TOMINAGA T, Nonaka T, Oyama S, Takamura Y, et al
    Utility of Drain Fluid Culture and Gram Stain in Early Intervention for Occult Anastomotic Leakage in Colorectal Cancer.
    Anticancer Res. 2022;42:3091-3098.
    PubMed     Abstract available


  28. OIKONOMAKIS I, Brodin D, Horer TM, Skoog P, et al
    Altered mRNA Expression Due to Rectal Perforation in a Porcine Model - A Pilot Study.
    Anticancer Res. 2022;42:2827-2833.
    PubMed     Abstract available


    May 2022
  29. WU MH, Chen CH, Chen CP, Huang TL, et al
    Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan.
    Anticancer Res. 2022;42:2375-2382.
    PubMed     Abstract available


  30. TAMAGAWA H, Aoyama T, Numata M, Kazama K, et al
    Impact of Infectious Complications on Survival and Recurrence of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2022;42:2763-2769.
    PubMed     Abstract available


  31. SATO S, Mikayama YO, Shiozawa M, Nukada S, et al
    Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer.
    Anticancer Res. 2022;42:2625-2635.
    PubMed     Abstract available


  32. SONODA H, Kitamura C, Kano K, Anzai H, et al
    Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.
    Anticancer Res. 2022;42:2461-2468.
    PubMed     Abstract available


  33. TANIOKA H, Shimada K, Tsuji A, Kochi M, et al
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    Anticancer Res. 2022;42:2675-2681.
    PubMed     Abstract available


  34. PETRAKIS G, Mantso T, Koukourakis MI, Panayiotidis MI, et al
    Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma.
    Anticancer Res. 2022;42:2363-2374.
    PubMed     Abstract available


    April 2022
  35. ESKELINEN M, Meklin J, Guimaraes DP, Selander T, et al
    The ColonView (CV) Quick Test for Fecal Occult Blood Shows Significantly Higher Diagnostic Accuracy in Detecting Distal than Proximal Colorectal Cancer.
    Anticancer Res. 2022;42:1879-1891.
    PubMed     Abstract available


  36. KATO A, Miyoshi N, Ohtsuru T, Sakai D, et al
    A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
    Anticancer Res. 2022;42:1859-1865.
    PubMed     Abstract available


  37. HONG JK, Kim DY, Shin JS, Ryu YS, et al
    CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.
    Anticancer Res. 2022;42:1813-1819.
    PubMed     Abstract available


  38. ISHIZAKI T, Katsumata K, Enomoto M, Mazaki J, et al
    Predictors of Lateral Pelvic Lymph Node Metastasis in Advanced Low Rectal Cancer Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:2113-2121.
    PubMed     Abstract available


  39. TACHIKAWA Y, Kawai K, Ozaki K, Nozawa H, et al
    CD133(+)HIF-1alpha(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer.
    Anticancer Res. 2022;42:2033-2043.
    PubMed     Abstract available


  40. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    PubMed     Abstract available


  41. KARAM E, Sindayigaya R, Giger-Pabst U, Gabriel M, et al
    Impact of Modern Management Strategies on the Clinical Outcome of Patients With Low Rectal Cancer - A Retrospective, Monocentric Cohort Study.
    Anticancer Res. 2022;42:1949-1963.
    PubMed     Abstract available


    March 2022
  42. MAEDA A, Takahashi H, Harata S, Watanabe K, et al
    The Interaction Between Cancer-associated Fibroblasts and Cancer Cells Enhances Bcl-xL and Mcl-1 in Colorectal Cancer.
    Anticancer Res. 2022;42:1277-1288.
    PubMed     Abstract available


  43. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    PubMed     Abstract available


  44. MATSUDA R, Kotsugi M, Nakase K, Morimoto T, et al
    Awake Craniotomy for Subcortical Brain Metastasis Beneath the Speech Center: A Technical Case Report.
    Anticancer Res. 2022;42:1641-1644.
    PubMed     Abstract available


  45. KATAYAMA H, Tominaga T, Nonaka T, Araki M, et al
    Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis.
    Anticancer Res. 2022;42:1527-1533.
    PubMed     Abstract available


  46. NACARKAHYA G, Borazan E, Horozoglu C, Yaylim I, et al
    Investigation of Long Non-coding RNAs H19 and LINC00675 in Colorectal Cancers in Terms of Histopathological Features and Correlations With Plasma Markers.
    Anticancer Res. 2022;42:1301-1306.
    PubMed     Abstract available


    February 2022
  47. LIANG JA, Kuo YC, Chao KSC, Chen WT, et al
    High vs. Standard Radiotherapy Dose in Locally Advanced Rectal Adenocarcinoma Patients Treated With Neoadjuvant Long Course Chemoradiotherapy: A Population-based Study.
    Anticancer Res. 2022;42:1143-1150.
    PubMed     Abstract available


  48. SHIRAISHI T, Ogawa H, Ozawa N, Suga K, et al
    Risk and Protective Factors for Postoperative Complications in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2022;42:1123-1130.
    PubMed     Abstract available


  49. TOMIOKA K, Aoki T, Watanabe M, Enami Y, et al
    Increased Transumbilical Incision Complication Rates With Laparoscopic Colorectal Resection: A Single-center Propensity Score-matched Cohort Study.
    Anticancer Res. 2022;42:1115-1121.
    PubMed     Abstract available


  50. DE FELICE F, Musio D, Iafrate F, Caponnetto S, et al
    Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis.
    Anticancer Res. 2022;42:991-1000.
    PubMed     Abstract available


  51. KOYAMA M, Osada E, Akiyama N, Eto K, et al
    Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:837-844.
    PubMed     Abstract available


  52. HAGIWARA T, Sugimoto K, Momose H, Irie T, et al
    CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Anticancer Res. 2022;42:697-707.
    PubMed     Abstract available


  53. GO G, Park HJ, Lee JH, Yun CW, et al
    Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
    Anticancer Res. 2022;42:857-866.
    PubMed     Abstract available


    January 2022
  54. HWANG J, Park A, Kim C, Yu D, et al
    Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.
    Anticancer Res. 2022;42:589-598.
    PubMed     Abstract available


  55. MIYOSHI K, Sato E, Katsumata K, Fukushima G, et al
    CD15(+) Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells.
    Anticancer Res. 2022;42:459-470.
    PubMed     Abstract available


  56. MULLER O, Sindayigaya R, Chomicki S, Karam E, et al
    Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma.
    Anticancer Res. 2022;42:155-164.
    PubMed     Abstract available


  57. MIYATA H, Akiyama Y, Iizuka A, Kondou R, et al
    Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
    Anticancer Res. 2022;42:419-427.
    PubMed     Abstract available


  58. BRESCIA A, Muttillo EM, Angelicone I, Madaffari I, et al
    The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis.
    Anticancer Res. 2022;42:211-216.
    PubMed     Abstract available


    December 2021
  59. SHIBUTANI M, En W, Okazaki Y, Kashiwagi S, et al
    The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Anticancer Res. 2021;41:6211-6216.
    PubMed     Abstract available


  60. ZENG X, Zhang L, Jia S, Lin T, et al
    Effects of Circulating 25(OH)D Status in Advanced Colorectal Cancer Patients Undergoing Chemotherapy: A Systematic Review.
    Anticancer Res. 2021;41:5903-5912.
    PubMed     Abstract available


  61. MATSUHASHI N, Takahashi T, Tanaka C, Yawata K, et al
    Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
    Anticancer Res. 2021;41:6247-6257.
    PubMed     Abstract available


    November 2021
  62. MAZAKI J, Katsumata K, Ohno Y, Udo R, et al
    A Novel Predictive Model for Anastomotic Leakage in Colorectal Cancer Using Auto-artificial Intelligence.
    Anticancer Res. 2021;41:5821-5825.
    PubMed     Abstract available


  63. KAWAMURA H, Honda M, Takiguchi K, Kamiga T, et al
    Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study.
    Anticancer Res. 2021;41:5693-5702.
    PubMed     Abstract available


  64. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    PubMed     Abstract available


  65. ISHIZAWA M, Hirayu A, Makishima M
    Zinc Inhibits Cadherin 1 Expression Induced by 1alpha,25-Dihydroxyvitamin D3 in Colon Cancer Cells.
    Anticancer Res. 2021;41:5453-5459.
    PubMed     Abstract available


  66. SUZUMURA H, Tsuruta M, Okabayashi K, Shigeta K, et al
    BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy.
    Anticancer Res. 2021;41:5445-5452.
    PubMed     Abstract available


  67. ROH SA, Kwon YH, Lee JL, Kim SK, et al
    SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
    Anticancer Res. 2021;41:5431-5444.
    PubMed     Abstract available


  68. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    PubMed     Abstract available


  69. AKAHOSHI S, Yamamura K, Komohara Y, Yoshii D, et al
    A Case Report of Metachronous Multiple Adenosquamous Carcinoma of the Colon Over-expressing PD-L1 and a Literature Review.
    Anticancer Res. 2021;41:5847-5854.
    PubMed     Abstract available


  70. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    PubMed     Abstract available


  71. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    PubMed     Abstract available


  72. OKAMOTO D, Matsuda T, Sawada R, Hasegawa H, et al
    Risk Factors for Complications Following Lateral Pelvic Lymph Node Dissection for Rectal Cancer.
    Anticancer Res. 2021;41:5599-5604.
    PubMed     Abstract available


  73. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The Automatically Analyzed (AA) ColonView (CV) Quick Test for Fecal Occult Blood Shows Higher Diagnostic Accuracy in Detection of Colorectal Adenoma than Visually Analyzed Tests.
    Anticancer Res. 2021;41:5517-5525.
    PubMed     Abstract available


    October 2021
  74. SATO S, Shiozawa M, Nukada S, Iguchi K, et al
    Preoperative Pre-albumin Concentration as a Predictor of Short-term Outcomes in Elderly Patients With Colorectal Cancer.
    Anticancer Res. 2021;41:5195-5202.
    PubMed     Abstract available


  75. ATSUMI Y, Numata M, Kazama K, Kawahara S, et al
    Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes?
    Anticancer Res. 2021;41:5097-5106.
    PubMed     Abstract available


  76. MEKLIN J, Eskelinen M, Guimaraes DP, Selander T, et al
    The New Generation Immunochemical Test for Fecal Occult Blood (ColonView Quick Test) Shows a High Diagnostic Accuracy in Colorectal Cancer Detection.
    Anticancer Res. 2021;41:5071-5079.
    PubMed     Abstract available


  77. NEUPANE P, Mimura K, Nakajima S, Okayama H, et al
    The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.
    Anticancer Res. 2021;41:4895-4905.
    PubMed     Abstract available


  78. TADA Y, Matsumi Y, Hara K, Miyauchi W, et al
    Infiltration of CD204-overexpressing Macrophages Contributes to the Progression of Stage II and III Colorectal Cancer.
    Anticancer Res. 2021;41:4857-4865.
    PubMed     Abstract available


  79. MIYAMOTO S, Fukui T, Horitani S, Tanimura Y, et al
    Linker Threonine-phosphorylated Smad2/3 Is a Biomarker of Colorectal Neoplastic Stem-like Cells that Correlates With Carcinogenesis.
    Anticancer Res. 2021;41:4789-4799.
    PubMed     Abstract available


  80. OZLUK E, Coppola D, Mohammad IZ, Islam T, et al
    Ethylmalonic Encephalopathy 1 Protein Is Increased in Colorectal Adenocarcinoma.
    Anticancer Res. 2021;41:4719-4723.
    PubMed     Abstract available


  81. SATO K, Miura T, Sakamoto Y, Morohashi H, et al
    Fascial Organisation and Lymphatic Systems Around the Pelvic Floor: A Literature Review.
    Anticancer Res. 2021;41:4705-4714.
    PubMed     Abstract available


  82. IIDA T, Murono K, Shiratori H, Nozawa H, et al
    Impact of Inferior Mesenteric Artery Occlusion on the Calibre of Collateral Arteries of the Colon.
    Anticancer Res. 2021;41:5189-5193.
    PubMed     Abstract available


  83. CHUNG YC, Ku YL, Chiang HC, Liu WC, et al
    Antibody to Interleukin-6 Receptor Inhibits In Vivo Growth of Human Colorectal Carcinoma Cell Xenografts.
    Anticancer Res. 2021;41:4907-4916.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: